Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Researchers at Harvard University, Department of Neurology target gene therapy
August 14th, 2007
Research findings, "Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector," are discussed in a new report. According to recent research from the United States, "Vectors based on herpes simplex virus type-1 (HSV-1) permit delivery of transgenes of up to 150 kb, while the inverted terminal repeats and Rep of the adeno-associated virus (AAV) can confer site-specific integration into the AAVS1 site, which allows sustained expression of a transgene. In this study, combination of the viral elements in HSV/AAV hybrid vectors has been applied for the infectious transfer of the human lysosomal beta-galactosidase (BGAL) gene of 100 kb."...
Source: Virus Weekly (2007-08-14)
|
